MitrAssist
Company

Last deal

$100.M

Amount

Series C

Stage

27.09.2023

Date

4

all rounds

$181.M

Total amount

General

About Company
MitrAssist has developed a minimally invasive approach to treating Mitral Regurgitation.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2009

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

MitrAssist's "valve-in-valve" approach overcomes the challenges of MR and offers an improved treatment solution for all MR patients. The company's innovative cardiac implant is designed to enhance valve functionality and has significant advantages over existing and in-development minimally invasive solutions. MitrAssist is a leading angiocarpy treatment devices platform with a globally recognized reputation for its cutting-edge innovation.
Contacts